Recent

% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • buzzoelvis buzzoelvis Apr 19, 2012 4:23 PM Flag

    Bsx Under valued, take out still alive!

    Bsx with EP slowly healing and litigation fading at under $6 is a steal. Growth, any growth brings tremendous leverage in a terribly difficult environment, Bard, Covidien, even Medtronic could be a suitor. Then Abbott will be forced to step forward with their partner St Judes.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • As of right now, Bard has a market cap of $8.26 billion and BSX has a market cap of $8.49 billion. Bard's annual revenue is less than $3 billion, and BSX's annual revenue is around $7.5 billion. You really think a significantly smaller company like Bard is going to buy BSX?

      You really think the FTC, SEC, and the EU would allow MDT to buy BSX? No anti-trust concerns with stents and ICDs??!!

      You really think the FTC, SEC, and the EU would allow ABT and STJ to buy BSX? No anti-trust concerns with stents and ICDs??!!

      BSX didn't grow revenue, if you actually read their revenue report. Why would anybody buy a sinking ship?

      As reported today:
      "US CRM sales were down 14% this quarter, worse than St. Jude's (-7%) performance (and Medtronic (MDT ) won't report for a while). ICD revenue fell 12% (St. Jude's fell 2%), indicating that BSX continues to lose share despite some controversy with St. Jude's leads."
      http://seekingalpha.com/article/510521-boston-scientific-has-the-tools-but-does-it-have-the-talent?source=yahoo

      "Global sales of coronary stent system (within Interventional Cardiology) at $387 million declined 5.8% due to disappointing performance from both drug-eluting stents (“DES”) that declined 4.2% to $363 million and bare-metal stents that plunged 20% to $24 million."
      http://finance.yahoo.com/news/boston-scientific-beats-penny-184527681.html

 
BSX
17.79-0.04(-0.22%)10:57 AMEDT